- Home
- PMM vs ATAI Comparison
PMM vs ATAI Comparison
Compare PMM & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMM
- ATAI
- Stock Information
- Founded
- PMM 1989
- ATAI 2018
- Country
- PMM United States
- ATAI Germany
- Employees
- PMM N/A
- ATAI N/A
- Industry
- PMM Investment Managers
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- PMM Finance
- ATAI Health Care
- Exchange
- PMM Nasdaq
- ATAI Nasdaq
- Market Cap
- PMM 284.9M
- ATAI 271.6M
- IPO Year
- PMM N/A
- ATAI 2021
- Fundamental
- Price
- PMM $6.24
- ATAI $1.34
- Analyst Decision
- PMM
- ATAI Strong Buy
- Analyst Count
- PMM 0
- ATAI 4
- Target Price
- PMM N/A
- ATAI $9.00
- AVG Volume (30 Days)
- PMM 118.3K
- ATAI 2.1M
- Earning Date
- PMM 01-01-0001
- ATAI 03-17-2025
- Dividend Yield
- PMM 4.68%
- ATAI N/A
- EPS Growth
- PMM N/A
- ATAI N/A
- EPS
- PMM 0.23
- ATAI N/A
- Revenue
- PMM N/A
- ATAI $308,000.00
- Revenue This Year
- PMM N/A
- ATAI N/A
- Revenue Next Year
- PMM N/A
- ATAI $20.00
- P/E Ratio
- PMM $26.52
- ATAI N/A
- Revenue Growth
- PMM N/A
- ATAI N/A
- 52 Week Low
- PMM $5.00
- ATAI $0.78
- 52 Week High
- PMM $6.42
- ATAI $2.85
- Technical
- Relative Strength Index (RSI)
- PMM 49.76
- ATAI 39.19
- Support Level
- PMM $6.10
- ATAI $1.34
- Resistance Level
- PMM $6.21
- ATAI $1.52
- Average True Range (ATR)
- PMM 0.06
- ATAI 0.11
- MACD
- PMM -0.01
- ATAI -0.02
- Stochastic Oscillator
- PMM 47.92
- ATAI 16.87
About PMM Putnam Managed Municipal Income Trust
Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.